Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to <i>in ovo</i> investigation.

ABSTRACT:

Introduction

Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer to treat because it lacks the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). A significant majority of deaths related to cancer are caused by tumor metastasis and angiogenesis. Vascular endothelial growth factor receptor 2 (VEGFR2) plays a significant role in angiogenesis. Instead of developing new molecules, drug repurposing, also known as repositioning, seeks innovative uses for outdated drugs or those that fail due to ineffectiveness.

Methods

In this study, we performed high-throughput virtual screening of FDA approved drug library taken from Enamine bioactive collection targeting VEGFR proteins, and the top hi

SUBMITTER: Jain A 

PROVIDER: S-EPMC12602248 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature